MOLOGEN AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases.
Our most important developments to date are the DNA immunomodulator MGN1703, which we are currently subjecting to clinical trials in the treatment of colorectal cancer and small-cell lung cancer. Furthermore our cell-based cancer therapy MGN1601 for the treatment of renal cancer, which is also a highly promising product, is currently undergoing clinical development as well.
The basis for our innovative drugs comes from our own MIDGE® and dSLIM® platform technologies and our own allogeneic tumor cell line. Our products all operate in accordance with the same principle of action: They enable a patient's immune system to fight the disease or pathogen itself. Our drugs, without exception, demonstrate excellent tolerability.
MOLOGEN AG was founded in 1998 and was one of the first biotechnology companies in Germany to be listed on the stock exchange immediately after its foundation. MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard on the Frankfurt Stock Exchange.
Over 50 employees are currently working at the company's headquarters in Berlin on the further development of our modern drug candidates.
With our unique, patented technologies and innovative product developments, we are one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies.